A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Gosuranemab (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PASSPORT
  • Sponsors Biogen; Bristol-Myers Squibb
  • Most Recent Events

    • 17 Apr 2018 According to a Biogen media release, data related to design of this trial will be presented at 70th annual meeting of the American Academy of Neurology (AAN).
    • 15 Mar 2018 According to a Biogen media release, data related to design of this trial will be presented at the Advances in Alzheimers and Parkinsons Therapies (AAT-AD/PD) Focus Meeting in Torino, Italy (March 15-18, 2018).
    • 03 Nov 2017 Planned primary completion date changed from 22 Apr 2019 to 8 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top